Efficient photodynamic therapy on human retinoblastoma cell lines
Jan Walther1, Stanislas Schastak1, Sladjana Dukic-Stefanovic1
1Department of Ophthalmology, Faculty of Medicine, University of Leipzig, Leipzig, Germany.
Plos One
|February 6, 2014
Summary
Photodynamic therapy (PDT) using tetrahydroporphyrin-tetratosylat (THPTS) effectively eliminated retinoblastoma cells in vitro. This new photosensitizer shows promise for eye-sparing retinoblastoma treatment.
Area of Science:
- Oncology
- Photochemistry
- Ophthalmology
Background:
- Photodynamic therapy (PDT) is a promising cancer treatment.
- Retinoblastoma often requires enucleation, especially when resistant to chemotherapy.
- A novel photosensitizer is needed for effective, eye-sparing retinoblastoma treatment.
Purpose of the Study:
- To investigate the in vitro photodynamic effect of a new cationic water-soluble photosensitizer, tetrahydroporphyrin-tetratosylat (THPTS).
- To evaluate THPTS efficacy on human retinoblastoma cells (Rb-1 and Y79) and normal retinal pigmented epithelium cells.
Main Methods:
- In vitro cell culture of human retinoblastoma and retinal pigmented epithelium cells.
- Incubation with THPTS followed by light irradiation.
- Assessment of cell proliferation and cytotoxicity.
Main Results:
- THPTS combined with light irradiation demonstrated maximal cytotoxic effect on retinoblastoma cells.
- Neither THPTS alone nor light irradiation alone affected cell proliferation.
- THPTS exhibited lower phototoxicity in normal retinal pigmented epithelium cells compared to cancer cells.
Conclusions:
- THPTS shows selective phototoxicity towards retinoblastoma cells.
- This photosensitizer holds potential for developing vision-preserving retinoblastoma therapies.
- Further in vivo studies are warranted to explore THPTS therapeutic potential.
